You’ve decided to try a GLP-1 medication for weight loss. You’ve read about semaglutide vs tirzepatide, you understand how they work, and you’re ready. Then you check your insurance formulary and find out it’s not covered — or it is, but only if your BMI exceeds 40. Welcome to the complicated world of GLP-1 insurance coverage in 2026.
The Coverage Paradox
Here’s the irony: as GLP-1 medications prove their value for more and more conditions — cardiovascular disease, liver disease, kidney protection — insurance coverage specifically for weight loss has actually become more restrictive. Multiple major insurers have tightened their BMI thresholds, increased prior authorization requirements, or removed anti-obesity medications from formularies altogether.
Key finding: According to a KFF Health Tracking Poll, approximately half of adults who have taken GLP-1 medications reported difficulty affording the cost.
Medicare: The Big Gap
The most significant coverage gap in 2026 remains Medicare Part D, which by law does not cover medications prescribed for weight loss. Period. This means that even though Wegovy is FDA-approved and clinically proven, Medicare beneficiaries cannot get it covered when prescribed for obesity. However, if a GLP-1 is prescribed for a covered indication — type 2 diabetes (Ozempic), cardiovascular risk reduction (Wegovy), or MASH/liver disease (Wegovy) — Medicare may cover it. Some physicians are already leveraging the cardiovascular indication to get Wegovy covered for patients who also have obesity.
The broader telehealth coverage landscape has improved with the Consolidated Appropriations Act of 2026 extending Medicare telehealth flexibilities through December 2027, but the medication exclusion remains.
Private Insurance: It Depends
Coverage varies wildly by insurer, plan, and state. Here’s the general picture:
More likely to cover GLP-1s for weight loss: Self-funded employer plans (large corporations), plans in states with obesity treatment parity laws, and plans that specifically list anti-obesity medications on their formulary.
Less likely to cover: Small group and individual marketplace plans, plans with high BMI thresholds (requiring BMI >40 or >35 with comorbidities), and plans that explicitly exclude weight loss medications.
Prior authorization is nearly universal. Even plans that do cover GLP-1s typically require documentation of prior weight loss attempts (usually 3-6 months of diet and exercise), lab work confirming BMI, and sometimes a referral from a specialist.
How Expanding Indications May Help
The FDA has been approving GLP-1 medications for additional conditions beyond weight loss. Wegovy is now approved for cardiovascular risk reduction (MACE events) and MASH (metabolic-associated steatohepatitis, previously called fatty liver disease). Ozempic is under review for peripheral artery disease. Each new approved indication creates another pathway for insurance coverage, because the medication is being prescribed for a covered condition — even if weight loss is a beneficial side effect.
Self-Pay Alternatives
For patients without insurance coverage, self-pay through telehealth platforms has become the most practical route. Here’s how the current cost landscape looks:
Oral Wegovy: Starting dose at $149/month (self-pay through Novo Nordisk’s program)
Injectable Wegovy: $199/month for starting doses (limited-time pricing through March 2026), then $349-499/month
Telehealth GLP-1 programs: Many platforms bundle the consultation, prescription, and medication into monthly programs, often at competitive rates compared to pharmacy pricing
HSA and FSA: Your Secret Weapon
If your employer offers a Health Savings Account (HSA) or Flexible Spending Account (FSA), GLP-1 medications prescribed by a physician are generally eligible expenses. This means you can pay with pre-tax dollars, effectively saving 20-35% depending on your tax bracket. It’s one of the most underutilized strategies for making these medications affordable.
Compare telehealth providers offering GLP-1 programs with transparent self-pay pricing — many include the consultation, prescription, and medication in one monthly fee.
Compare Providers →What You Can Do Right Now
Call your insurer and ask specifically about “anti-obesity medication coverage” on your plan. Ask about BMI thresholds and prior authorization requirements. If coverage is denied, ask your prescribing physician about appealing the decision or prescribing for a covered indication (if you have qualifying cardiovascular risk or other comorbidities). And explore self-pay telehealth platforms — in many cases, they’re more affordable than you’d expect, especially with oral Wegovy’s lower price point.